Ascendis gets FDA orphan drug status for Yorvipath for hypothyroidism09/12/2024 Ascendis gets FDA orphan drug status for Yorvipath for hypothyroidism Source: Seekingalpha
Ascendis gets FDA orphan drug status for Yorvipath for hypothyroidism (NASDAQ:ASND)09/12/2024 Iryna Drozd The FDA has granted Orphan Drug Designation to Ascendis Pharma (ASND) for its prodrug Yorvipath for the therapy of hypothyroidism in adults. Yorvipath is…
